Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cMet-vc-MMAE
- Development stage
- Preclinical
- Lead developer
- Triphase Accelerator
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
cMet-vc-MMAE is an antibody-drug conjugate (ADC) designed to target the c-Met receptor (hepatocyte growth factor receptor). It consists of a monoclonal antibody specific for c-Met conjugated to the microtubule-disrupting agent monomethyl auristatin E (MMAE) via a cathepsin-cleavable valine-citrulline (vc) linker. While MMAE-based ADCs are clinically validated in other contexts, cMet-vc-MMAE is primarily utilized as a preclinical research tool or benchmark comparator in studies evaluating next-generation c-Met-targeted therapies, such as those utilizing pyrrolobenzodiazepine (PBD) payloads. In preclinical models, it has demonstrated antitumor activity in c-Met-expressing cell lines and lung cancer xenografts, although its potency is often lower than newer ADC constructs in environments with low-to-medium c-Met expression.
- Other names
- anti-cMet-vc-MMAEc-Met-vc-MMAE
02
Targets
TUBB (Tubulin (alpha and beta subunits))MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on cMet-vc-MMAE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cMet-vc-MMAE.